361 related articles for article (PubMed ID: 31960186)
1. TERT promoter hotspot mutations and their relationship with TERT levels and telomere erosion in patients with head and neck squamous cell carcinoma.
Boscolo-Rizzo P; Giunco S; Rampazzo E; Brutti M; Spinato G; Menegaldo A; Stellin M; Mantovani M; Bandolin L; Rossi M; Del Mistro A; Tirelli G; Dei Tos AP; Guerriero A; Niero M; Da Mosto MC; Polesel J; De Rossi A
J Cancer Res Clin Oncol; 2020 Feb; 146(2):381-389. PubMed ID: 31960186
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of promoter mutations in the TERT gene in oral cavity squamous cell carcinoma.
Chang KP; Wang CI; Pickering CR; Huang Y; Tsai CN; Tsang NM; Kao HK; Cheng MH; Myers JN
Head Neck; 2017 Jun; 39(6):1131-1137. PubMed ID: 28230921
[TBL] [Abstract][Full Text] [Related]
3. TERT promoter hot spot mutations are frequent in Indian cervical and oral squamous cell carcinomas.
Vinothkumar V; Arunkumar G; Revathidevi S; Arun K; Manikandan M; Rao AK; Rajkumar KS; Ajay C; Rajaraman R; Ramani R; Murugan AK; Munirajan AK
Tumour Biol; 2016 Jun; 37(6):7907-13. PubMed ID: 26700669
[TBL] [Abstract][Full Text] [Related]
4. TERT promoter mutations in head and neck squamous cell carcinoma: A systematic review and meta-analysis on prevalence and prognostic significance.
Boscolo-Rizzo P; Tirelli G; Polesel J; Sia E; Phillips V; Borsetto D; De Rossi A; Giunco S
Oral Oncol; 2023 May; 140():106398. PubMed ID: 37075587
[TBL] [Abstract][Full Text] [Related]
5. Promoter region mutations of the telomerase reverse transcriptase (TERT) gene in head and neck squamous cell carcinoma.
Yilmaz I; Erkul BE; Ozturk Sari S; Issin G; Tural E; Terzi Kaya Terzi N; Karatay H; Celik M; Ulusan M; Bilgic B
Oral Surg Oral Med Oral Pathol Oral Radiol; 2020 Jul; 130(1):63-70. PubMed ID: 32404253
[TBL] [Abstract][Full Text] [Related]
6. hTERT C250T promoter mutation and telomere length as a molecular markers of cancer progression in patients with head and neck cancer.
Barczak W; Suchorska WM; Sobecka A; Bednarowicz K; Machczynski P; Golusinski P; Rubis B; Masternak MM; Golusinski W
Mol Med Rep; 2017 Jul; 16(1):441-446. PubMed ID: 28535013
[TBL] [Abstract][Full Text] [Related]
7. Distinct profiles of TERT promoter mutations and telomerase expression in head and neck cancer and cervical carcinoma.
Annunziata C; Pezzuto F; Greggi S; Ionna F; Losito S; Botti G; Buonaguro L; Buonaguro FM; Tornesello ML
Int J Cancer; 2018 Sep; 143(5):1153-1161. PubMed ID: 29603728
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological characteristics of TERT promoter mutation and telomere length in hepatocellular carcinoma.
Lee HW; Park TI; Jang SY; Park SY; Park WJ; Jung SJ; Lee JH
Medicine (Baltimore); 2017 Feb; 96(5):e5766. PubMed ID: 28151853
[TBL] [Abstract][Full Text] [Related]
9. TERT promoter mutation in patients with second primary of tongue squamous cell carcinoma.
Erkul E; Yilmaz I
Oral Oncol; 2021 Mar; 114():105089. PubMed ID: 33189577
[TBL] [Abstract][Full Text] [Related]
10. The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas.
Liu T; Wang N; Cao J; Sofiadis A; Dinets A; Zedenius J; Larsson C; Xu D
Oncogene; 2014 Oct; 33(42):4978-84. PubMed ID: 24141777
[TBL] [Abstract][Full Text] [Related]
11. Mutations in TERT promoter and FGFR3 and telomere length in bladder cancer.
Hosen I; Rachakonda PS; Heidenreich B; de Verdier PJ; Ryk C; Steineck G; Hemminki K; Kumar R
Int J Cancer; 2015 Oct; 137(7):1621-9. PubMed ID: 25809917
[TBL] [Abstract][Full Text] [Related]
12. Frequent TERT Promoter Mutations in Ocular Surface Squamous Neoplasia.
Scholz SL; Thomasen H; Reis H; Möller I; Darawsha R; Müller B; Dekowski D; Sucker A; Schilling B; Schadendorf D; Steuhl KP; Paschen A; Westekemper H; Meller D; Griewank KG
Invest Ophthalmol Vis Sci; 2015 Sep; 56(10):5854-61. PubMed ID: 26348634
[TBL] [Abstract][Full Text] [Related]
13. Telomerase reverse transcriptase promoter mutations in tumors originating from the adrenal gland and extra-adrenal paraganglia.
Papathomas TG; Oudijk L; Zwarthoff EC; Post E; Duijkers FA; van Noesel MM; Hofland LJ; Pollard PJ; Maher ER; Restuccia DF; Feelders RA; Franssen GJ; Timmers HJ; Sleijfer S; de Herder WW; de Krijger RR; Dinjens WN; Korpershoek E
Endocr Relat Cancer; 2014 Aug; 21(4):653-61. PubMed ID: 24951106
[TBL] [Abstract][Full Text] [Related]
14. Telomere length assessment and molecular characterization of TERT gene promoter in periampullary carcinomas.
Gregório C; Thakur S; Camara Rivero R; Márcia Dos Santos Machado S; Cuenin C; Carreira C; White V; Cree IA; Vukojevic K; Glavina Durdov M; Bersch Osvaldt A; Ashton-Prolla P; Herceg Z; Talukdar FR
Gene; 2023 Jul; 873():147460. PubMed ID: 37150235
[TBL] [Abstract][Full Text] [Related]
15.
Yu Y; Fan D; Song X; Zakeri K; Chen L; Kang J; McBride S; Tsai CJ; Dunn L; Sherman E; Katabi N; Dogan S; Cracchiolo J; Cohen M; Boyle JO; Lee M; Valero C; Wang J; Wong R; Morris L; Riaz N; Lee N
JCO Precis Oncol; 2021 Aug; 5():. PubMed ID: 34381934
[TBL] [Abstract][Full Text] [Related]
16. Telomere shortening in mucosa surrounding the tumor: biosensor of field cancerization and prognostic marker of mucosal failure in head and neck squamous cell carcinoma.
Boscolo-Rizzo P; Rampazzo E; Perissinotto E; Piano MA; Giunco S; Baboci L; Spinato G; Spinato R; Tirelli G; Da Mosto MC; Del Mistro A; De Rossi A
Oral Oncol; 2015 May; 51(5):500-7. PubMed ID: 25771075
[TBL] [Abstract][Full Text] [Related]
17. TERT promoter hypermethylation is associated with poor prognosis in adrenocortical carcinoma.
Svahn F; Paulsson JO; Stenman A; Fotouhi O; Mu N; Murtha TD; Korah R; Carling T; Bäckdahl M; Wang N; Juhlin CC; Larsson C
Int J Mol Med; 2018 Sep; 42(3):1675-1683. PubMed ID: 29956721
[TBL] [Abstract][Full Text] [Related]
18. Telomeres and telomerase in head and neck squamous cell carcinoma: from pathogenesis to clinical implications.
Boscolo-Rizzo P; Da Mosto MC; Rampazzo E; Giunco S; Del Mistro A; Menegaldo A; Baboci L; Mantovani M; Tirelli G; De Rossi A
Cancer Metastasis Rev; 2016 Sep; 35(3):457-74. PubMed ID: 27501725
[TBL] [Abstract][Full Text] [Related]
19. Telomere length, telomerase reverse transcriptase promoter mutations, and melanoma risk.
Rachakonda S; Kong H; Srinivas N; Garcia-Casado Z; Requena C; Fallah M; Heidenreich B; Planelles D; Traves V; Schadendorf D; Nagore E; Kumar R
Genes Chromosomes Cancer; 2018 Nov; 57(11):564-572. PubMed ID: 30203894
[TBL] [Abstract][Full Text] [Related]
20. Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome.
Allory Y; Beukers W; Sagrera A; Flández M; Marqués M; Márquez M; van der Keur KA; Dyrskjot L; Lurkin I; Vermeij M; Carrato A; Lloreta J; Lorente JA; Carrillo-de Santa Pau E; Masius RG; Kogevinas M; Steyerberg EW; van Tilborg AA; Abas C; Orntoft TF; Zuiverloon TC; Malats N; Zwarthoff EC; Real FX
Eur Urol; 2014 Feb; 65(2):360-6. PubMed ID: 24018021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
